These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10462249)

  • 41. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine.
    Greenway TE; Eldridge JH; Ludwig G; Staas JK; Smith JF; Gilley RM; Michalek SM
    Vaccine; 1998 Aug; 16(13):1314-23. PubMed ID: 9682396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinetics of cytokine expression and regulation of host protection following infection with molecularly cloned Venezuelan equine encephalitis virus.
    Grieder FB; Davis BK; Zhou XD; Chen SJ; Finkelman FD; Gause WC
    Virology; 1997 Jul; 233(2):302-12. PubMed ID: 9217054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1.
    Davis NL; Brown KW; Greenwald GF; Zajac AJ; Zacny VL; Smith JF; Johnston RE
    Virology; 1995 Sep; 212(1):102-10. PubMed ID: 7676619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product.
    Perkins SD; Williams AJ; O'Brien LM; Laws TR; Phillpotts RJ
    Viral Immunol; 2008 Dec; 21(4):451-7. PubMed ID: 19115934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.
    Irwin MJ; Laube LS; Lee V; Austin M; Chada S; Anderson CG; Townsend K; Jolly DJ; Warner JF
    J Virol; 1994 Aug; 68(8):5036-44. PubMed ID: 8035504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.
    Olinger GG; Bailey MA; Dye JM; Bakken R; Kuehne A; Kondig J; Wilson J; Hogan RJ; Hart MK
    J Virol; 2005 Nov; 79(22):14189-96. PubMed ID: 16254354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alphavirus replicon particles as candidate HIV vaccines.
    Davis NL; West A; Reap E; MacDonald G; Collier M; Dryga S; Maughan M; Connell M; Walker C; McGrath K; Cecil C; Ping LH; Frelinger J; Olmsted R; Keith P; Swanstrom R; Williamson C; Johnson P; Montefiori D; Johnston RE
    IUBMB Life; 2002; 53(4-5):209-11. PubMed ID: 12120997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
    Muthumani K; Zhang D; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB
    Virology; 2003 Sep; 314(1):134-46. PubMed ID: 14517067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector.
    Tähtinen M; Strengell M; Collings A; Pitkänen J; Kjerrström A; Hakkarainen K; Peterson P; Kohleisen B; Wahren B; Ranki A; Ustav M; Krohn K
    Vaccine; 2001 Feb; 19(15-16):2039-47. PubMed ID: 11228375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
    Kim BJ; Kim BR; Kook YH; Kim BJ
    Front Immunol; 2018; 9():643. PubMed ID: 29636755
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The immunogenic properties of a recombinant vaccinia virus with an incorporated DNA copy of the 26S RNA of the Venezuelan equine encephalomyelitis virus].
    Sviatchenko VA; Agapov EV; Urmanov IKh; Serpinskiĭ OI; Frolov IV; Kolykhalov AA; Ryzhikov AB; Netesov SV
    Vopr Virusol; 1993; 38(5):222-6. PubMed ID: 8284922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
    Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
    J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
    Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
    J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heterologous gene expression from transmissible gastroenteritis virus replicon particles.
    Curtis KM; Yount B; Baric RS
    J Virol; 2002 Feb; 76(3):1422-34. PubMed ID: 11773416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
    J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Attenuated Salmonella enteritidis E23 as a vehicle for the rectal delivery of DNA vaccine coding for HIV-1 polyepitope CTL immunogen.
    Karpenko LI; Danilenko AV; Bazhan SI; Danilenko ED; Sysoeva GM; Kaplina ON; Volkova OY; Oreshkova SF; Ilyichev AA
    Microb Biotechnol; 2012 Mar; 5(2):241-50. PubMed ID: 21895998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.